Tianjin Finder Chemical TFC
Finnrick has tested 57 samples from Tianjin Finder Chemical TFC across 4 products.
Finnrick Vendor Profile
to
Tianjin Finder Chemical TFC
Tracking 4 products
57 total samples tested
Last test 4 Dec 2025
Take Action
Test My Sample
Researcher
Request Full Data Access to the Finnrick database of peptide tests.
Products
| Tests | ||||||||
|---|---|---|---|---|---|---|---|---|
| Product | Rating | Count | Avg | Min | Max | Oldest | Most Recent | |
| GHK-Cu | 4 | 16 Jul 2025 | 4 Aug 2025 | |||||
| Retatrutide | 20 | 11 Jun 2025 | 4 Dec 2025 | |||||
| Tirzepatide | 27 | 11 Jun 2025 | 6 Nov 2025 | |||||
| BPC-157 | 6 | 29 Jun 2025 | 2 Dec 2025 | |||||
Most recent Tianjin Finder Chemical TFC tests
Samples are tested in commercial labs
57
tests
4
products
Scores
AVGMINMAX
First
11 Jun 2025
Last
4 Dec 2025
| Quantity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Test Date | Product | Certificate | Test Score | Label | Tested | Difference | Purity | Batch ID | Container | Tested At | Sent By |
| 4 Dec 2025 | Retatrutide | View | 10mg | 10.100mg | +1.0% | 99.95% | (no batch ID) | No Label / Silver Crimp / White Cap | Lab E | Public | |
| 2 Dec 2025 | BPC-157 | View | 10mg | 13.800mg | +38.0% | 98.60% | (no batch ID) | No Label / Silver Crimp / Clear Yellow Cap | Lab G | Public | |
| 25 Nov 2025 | Retatrutide | View | 20mg | 21.200mg | +6.0% | 99.95% | (no batch ID) | No Label / Silver Crimp / Blue Cap | Lab E | Public | |
| 25 Nov 2025 | Retatrutide | View | 20mg | 41.500mg | +107.5% | 99.95% | 8508E111 | Silver Label / Silver Crimp / Blue Cap | Lab E | Public | |
| 17 Nov 2025 | Retatrutide | View | 10mg | 9.360mg | -6.4% | 99.95% | 85081100 | Silver Label / Silver Crimp / White Cap | Lab E | Public | |
| 6 Nov 2025 | Tirzepatide | View | 30mg | 32.600mg | +8.7% | 99.95% | (no batch ID) | No Label / Silver Crimp / Orange Cap | Lab E | Public | |
| 4 Nov 2025 | Tirzepatide | View | 30mg | 33.900mg | +13.0% | 99.91% | TFC/Tirz/070925 | No Label / Silver Crimp / Orange Cap | Lab E | Public | |